TELA Bio Stock

TELA Bio ROE

The Return on Equity (ROE) of TELA Bio (TELA) as of Aug 20, 2026 is -615.10 %. In the previous year, Return on Equity (ROE) was -132.97 % — a change of 362.58% (lower).

ROE

-615.10 %

YoY

362.58%

Last updated:

In 2026, TELA Bio's return on equity (ROE) was -615.10 %, a 362.58% increase from the -132.97 % ROE in the previous year.

Access this data via the Eulerpool API

TELA Bio Stock analysis

What does TELA Bio do? TELA Bio Inc is an American medical technology company that specializes in the development and manufacture of innovative surgical implants. The history of this company began in 2012 when a group of experienced bioengineers and medical professionals decided to develop a better surgical tissue replacement material. The idea was to create a product that not only supports the healing process but is also safe, durable, and easy to handle. Over the years, TELA Bio has successfully implemented the business model of complete vertical integration, which means that the company takes care of everything from research and development to production, distribution, and marketing of its products. This allows the company to build closer relationships with its customers and improve the quality of its products by addressing the needs and requirements of its users. The core business of TELA Bio focuses on a wide range of surgical tissue replacement materials specifically designed for plastic and reconstructive surgery, hernia repair, and wound healing. These products are characterized by their high biocompatibility, strength, and flexibility, and provide a safe and effective solution for a variety of medical applications. Key products offered by TELA Bio include the OviTex® product family, which includes surgical mesh materials for supporting wound healing in hernia repairs and abdominal surgeries, as well as tissue replacement materials for breast reconstruction after mastectomy. These products are known for their high biocompatibility and ability to integrate into the surrounding tissue and restore natural tissue structures. In addition, TELA Bio also offers the TELADERM®-DH product, specifically developed for wound healing in diabetes patients. This product consists of a tissue replacement material that supports skin repair and reduces the risk of infection, particularly in patients with poorly healing wounds. Overall, TELA Bio has developed a wide range of products tailored to the needs of modern medicine. The company is focused on improving the quality of medical care and providing innovative solutions for surgical wound healing. With its successful implementations in research, production, and distribution, TELA Bio is well-positioned to continue growing and solidify its position as a leading provider of medical implants. TELA Bio is one of the most popular companies on Eulerpool.

ROE Details

Decoding TELA Bio's Return on Equity (ROE)

TELA Bio's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing TELA Bio's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

TELA Bio's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in TELA Bio’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about TELA Bio stock

Return on Equity (ROE) of TELA Bio is -615.10 % in 2026.

Return on Equity (ROE) of TELA Bio changed from -132.97 % to -615.10 %, representing a 362.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) TELA Bio since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s TELA Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — TELA Bio

All Key Metrics — TELA Bio